Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.84 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.75 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074389 | 1.00 | RARB (0.97) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8943017 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8535621 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL2354189 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7172427 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL4185457 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL641904 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5828640 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5858775 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8532269 | 0.98 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160098-B | Oxygen-containing compound deoxidization methylation method | 中国科学院兰州化学物理研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-115160098-A | Oxygen-containing compound deoxidation and methylation method | 中国科学院兰州化学物理研究所 | 2022-10-11 | — | — | CN | disclosed |
| US-9939555-B2 | Cinnamic acid derivative, polymer thereof, and liquid crystal alignment layer comprising cured product thereof | DIC CORPORATION (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2727947-A1 | COPOLYMER, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING HARDENED PRODUCT THEREOF | DIC Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2674437-A1 | Novel antibacterial agents for the treatment of GRAM positive infections | Cubist Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2379580-B1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARM INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2379580-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | Cubist Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-5569646-A | TREATMENT OF PNEUMONIA; MICROBIOCIDES, FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| US-5412144-A | Organic materials with nonlinear optical properties | THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0640676-A1 | Mesomorphic compound, liquid crystal composition containing the compound, liquid crystal device using the composition, liquid crystal apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1995-03-01 | — | — | EP | disclosed |
| EP-0311329-B1 | Liquid crystal compositions comprising optically active 1-[2-halogen-substituted-phenyl]-ethanols and derivatives thereof | CHISSO CORP (JP) | 1994-05-04 | — | — | EP | disclosed |
| US-4904409-A | LIQUID CRYSTAL HAS HIGH TWISTABILITY | CHISSO CORPORATION (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0311329-A2 | Liquid crystal compositions comprising optically active 1-[2-halogen-substituted-phenyl]-ethanols and derivatives thereof | Chisso Corporation (JP) | 1989-04-12 | — | — | EP | disclosed |
| US-4225454-A | Ortho-cyanophenyl biphenylcarboxylate liquid crystal esters and mixtures thereof | HUGHES AIRCRAFT COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| US-4136053-A | BIPHENYL ESTERS AND LIQUID CRYSTALLINE MIXTURES COMPRISING THEM | MERCK PATENT GESELLSCHAFT MIT BESCHANKTER HAFTUNG (DE) | 1979-01-23 | — | — | US | disclosed |
| US-4065489-A | Biphenyl esters and liquid crystalline mixtures comprising them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885TP53 4408/4885TSHR 4677/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885TP53 4408/4885TSHR 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.